Navigation Links
Pharmaxis Investor Conference Call

SYDNEY, July 21 /PRNewswire-Asia/ -- Pharmaxis Ltd (ASX: PXS) will release its June 2009 Quarterly Report to Shareholders on the afternoon of Wednesday 22nd July 2009. Dr Alan Robertson will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday 23rd July at 8.00am (Sydney), (Wednesday 22nd July at 6.00pm U.S. East Coast, 3.00pm U.S. West Coast).

    Telephone access (toll free) details are below:

    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    Online (global access):

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.


     Pharmaxis Investor Relations
     Tel:     +61-2-9454-7200
     Fax:     +61-2-9451-3622

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmaxis to Voluntarily De-List from Nasdaq
2. Pharmaxis Closes Share Purchase Plan
3. Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
4. New Pharmaxis Board Appointment
5. Pharmaxis Investor Conference Call
6. Pharmaxis Appoints French Distributor for Aridol(TM)
7. Pharmaxis Builds Senior Management Team
8. Pharmaxis Investor Conference Call
9. Pharmaxis Aridol Approved for Sale in Switzerland
10. Pharmaxis Investor Conference Call
11. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
Post Your Comments:
(Date:11/30/2015)... -- Champions Oncology, Inc. (CSBR), engaged in the development of ... and use of oncology drugs, today announced that ... at the LD MICRO Investor Conference on Wednesday, December ... conference, held at the Luxe Sunset Bel Air Hotel ... feature 200 small/micro-cap companies and is expected to host ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, ... in Vienna, Austria to be ... owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced ... Therapy Suite at the 3rd European Congress of NeuroRehabilitation ...
(Date:11/30/2015)... PETACH TIKVAH, Israel , Nov. 30, 2015 ... ), a leading developer of adult stem cell technologies for ... Therapeutics Ltd., has been awarded an additional grant of approximately ... Chief Scientist (OCS). This grant, the second this year, brings ... to approximately $1.8 million (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):